Capricor Therapeutics Debt to Equity Ratio 2010-2024 | CAPR
Current and historical debt to equity ratio values for Capricor Therapeutics (CAPR) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Capricor Therapeutics debt/equity for the three months ending September 30, 2024 was 0.00.
| Capricor Therapeutics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $0.03B | $0.07B | 0.36 |
| 2024-06-30 | $0.03B | $0.01B | 2.33 |
| 2024-03-31 | $0.03B | $0.02B | 1.68 |
| 2023-12-31 | $0.04B | $0.02B | 1.60 |
| 2023-09-30 | $0.04B | $-0.00B | -21.78 |
| 2023-06-30 | $0.04B | $0.00B | 15.85 |
| 2023-03-31 | $0.05B | $0.01B | 7.68 |
| 2022-12-31 | $0.04B | $0.01B | 3.25 |
| 2022-09-30 | $0.04B | $0.02B | 2.50 |
| 2022-06-30 | $0.04B | $0.02B | 2.10 |
| 2022-03-31 | $0.04B | $0.03B | 1.64 |
| 2021-12-31 | $0.01B | $0.03B | 0.32 |
| 2021-09-30 | $0.01B | $0.04B | 0.17 |
| 2021-06-30 | $0.01B | $0.03B | 0.20 |
| 2021-03-31 | $0.01B | $0.04B | 0.20 |
| 2020-12-31 | $0.01B | $0.03B | 0.23 |
| 2020-09-30 | $0.01B | $0.03B | 0.19 |
| 2020-06-30 | $0.01B | $0.03B | 0.17 |
| 2020-03-31 | $0.01B | $0.01B | 0.49 |
| 2019-12-31 | $0.00B | $0.01B | 0.63 |
| 2019-09-30 | $0.00B | $0.00B | 1.22 |
| 2019-06-30 | $0.01B | $0.00B | 2.09 |
| 2019-03-31 | $0.01B | $0.00B | 1.30 |
| 2018-12-31 | $0.01B | $0.01B | 1.00 |
| 2018-09-30 | $0.01B | $0.01B | 0.75 |
| 2018-06-30 | $0.01B | $0.01B | 0.49 |
| 2018-03-31 | $0.01B | $0.01B | 0.46 |
| 2017-12-31 | $0.01B | $0.01B | 0.45 |
| 2017-09-30 | $0.02B | $-0.00B | -4.70 |
| 2017-06-30 | $0.02B | $-0.01B | -3.16 |
| 2017-03-31 | $0.02B | $-0.01B | -2.96 |
| 2016-12-31 | $0.02B | $-0.00B | -5.68 |
| 2016-09-30 | $0.02B | $0.00B | 497.41 |
| 2016-06-30 | $0.02B | $-0.01B | -3.72 |
| 2016-03-31 | $0.02B | $-0.00B | -16.69 |
| 2015-12-31 | $0.02B | $-0.00B | -16.57 |
| 2015-09-30 | $0.02B | $0.00B | 9.33 |
| 2015-06-30 | $0.02B | $0.01B | 4.20 |
| 2015-03-31 | $0.02B | $0.01B | 2.75 |
| 2014-12-31 | $0.02B | $-0.01B | -3.18 |
| 2014-09-30 | $0.02B | $-0.00B | -4.64 |
| 2014-06-30 | $0.02B | $-0.00B | -6.98 |
| 2014-03-31 | $0.02B | $-0.00B | -10.63 |
| 2013-12-31 | $0.01B | $-0.00B | -11.35 |
| 2013-09-30 | $0.00B | $-0.00B | -1.07 |
| 2013-06-30 | $0.00B | $-0.00B | -1.24 |
| 2013-03-31 | $0.00B | $-0.00B | -1.65 |
| 2012-12-31 | $0.00B | $0.01B | 0.11 |
| 2012-09-30 | $0.00B | $0.00B | 17.21 |
| 2012-06-30 | $0.00B | $0.00B | 0.84 |
| 2012-03-31 | $0.00B | $0.00B | 2.10 |
| 2011-12-31 | $0.00B | $0.00B | 0.65 |
| 2011-09-30 | $0.00B | $0.00B | 0.30 |
| 2011-06-30 | $0.00B | $0.00B | 0.13 |
| 2011-03-31 | $0.00B | $0.00B | 0.44 |
| 2010-12-31 | $0.00B | $0.00B | 0.41 |
| 2010-09-30 | $0.00B | $0.00B | 0.46 |
| 2010-06-30 | $0.00B | $0.01B | 0.24 |
| 2010-03-31 | $0.00B | $0.00B | 0.60 |
| 2009-12-31 | $0.00B | $0.00B | 0.21 |
| 2009-09-30 | $0.00B | $0.00B | 0.21 |
| 2009-06-30 | $0.00B | $0.00B | 0.24 |
| 2009-03-31 | $0.00B | $0.00B | 0.22 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.678B | $0.025B |
| Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $204.284B | 25.22 |
| Stryker (SYK) | United States | $148.861B | 33.55 |
| Boston Scientific (BSX) | United States | $147.840B | 42.50 |
| EssilorLuxottica (ESLOY) | France | $120.398B | 0.00 |
| Medtronic (MDT) | Ireland | $112.636B | 16.73 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.153B | 0.00 |
| Haleon (HLN) | United Kingdom | $41.736B | 27.12 |
| GE HealthCare Technologies (GEHC) | United States | $39.899B | 20.69 |
| ResMed (RMD) | United States | $36.307B | 29.83 |
| Terumo (TRUMY) | Japan | $28.860B | 40.76 |
| Koninklijke Philips (PHG) | Netherlands | $24.692B | 18.90 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.842B | 13.91 |
| Insulet (PODD) | United States | $19.563B | 77.90 |
| Baxter (BAX) | United States | $16.252B | 10.57 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.030B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $10.094B | 34.30 |
| BellRing Brands (BRBR) | United States | $9.817B | 39.50 |
| Demant (WILYY) | Denmark | $8.735B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.632B | 15.41 |
| ICU Medical (ICUI) | United States | $4.089B | 38.93 |
| Prestige Consumer Healthcare (PBH) | United States | $3.823B | 19.01 |
| Haemonetics (HAE) | United States | $3.684B | 17.98 |
| Envista Holdings (NVST) | United States | $3.623B | 26.99 |
| Perrigo (PRGO) | Ireland | $3.281B | 9.66 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.992B | 19.25 |
| GN Store Nord (GNNDY) | Denmark | $2.797B | 17.94 |
| Neogen (NEOG) | United States | $2.592B | 29.88 |
| LeMaitre Vascular (LMAT) | United States | $2.203B | 53.55 |
| AtriCure (ATRC) | United States | $1.926B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.514B | 26.50 |
| InMode (INMD) | Israel | $1.434B | 8.62 |
| AdaptHealth (AHCO) | United States | $1.368B | 9.78 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.343B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.274B | 0.00 |
| Owens & Minor (OMI) | United States | $1.145B | 8.95 |
| Curaleaf Holdings (CURLF) | Canada | $0.903B | 0.00 |
| Evolus (EOLS) | United States | $0.895B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.881B | 15.54 |
| CeriBell (CBLL) | United States | $0.833B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.572B | 25.24 |
| Omeros (OMER) | United States | $0.538B | 0.00 |
| Surmodics (SRDX) | United States | $0.530B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.434B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.418B | 0.00 |
| ZimVie (ZIMV) | United States | $0.391B | 32.91 |
| Quanterix (QTRX) | United States | $0.386B | 0.00 |
| Valneva SE (VALN) | France | $0.376B | 0.00 |
| Cerus (CERS) | United States | $0.336B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.330B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.317B | 30.11 |
| Biote (BTMD) | United States | $0.307B | 6.73 |
| OraSure Technologies (OSUR) | United States | $0.290B | 19.45 |
| Canopy Growth (CGC) | Canada | $0.263B | 0.00 |
| Zynex (ZYXI) | United States | $0.261B | 54.53 |
| High Tide (HITI) | Canada | $0.244B | 100.33 |
| Sanuwave Health (SNWV) | United States | $0.233B | 3.28 |
| Utah Medical Products (UTMD) | United States | $0.213B | 14.71 |
| Aurora Cannabis (ACB) | Canada | $0.212B | 0.00 |
| Brainsway (BWAY) | Israel | $0.208B | 110.50 |
| Organigram Holdings (OGI) | Canada | $0.198B | 0.00 |
| MacroGenics (MGNX) | United States | $0.193B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.153B | 0.00 |
| Veru (VERU) | United States | $0.152B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 18.29 |
| Jin Medical (ZJYL) | China | $0.136B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.127B | 0.00 |
| Fonar (FONR) | United States | $0.097B | 11.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| InterCure (INCR) | Israel | $0.078B | 0.00 |
| INLIF (INLF) | $0.074B | 0.00 | |
| Exagen (XGN) | United States | $0.071B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.070B | 36.33 |
| Apyx Medical (APYX) | United States | $0.057B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.057B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.046B | 0.00 |
| Modular Medical (MODD) | United States | $0.043B | 0.00 |
| Safety Shot (SHOT) | United States | $0.029B | 0.00 |
| Nephros (NEPH) | United States | $0.017B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.015B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 14.07 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |